Auch wir verwenden Cookies. Mehr Informationen in der Datenschutzerklärung

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

3 Overlooked Stocks Set to Soar in 2026

TheMotleyFool

0 0

3 Overlooked Stocks Set to Soar in 2026Photo, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors.

Axsome Therapeutics (NASDAQ: AXSM) is a mid-cap with only three approved therapies, while small-cap stock NovoCure (NASDAQ: NVCR) has approvals in four indications for its Tumor Treating Fields, and small-cap MBX Biosciences (NASDAQ: MBX) has several late-stage therapies in its pipeline. I like their potential and believe the markets haven't fully digested recent positive news for the trio.

Here's why I think each of these stocks could soar in 2026.

Source Fool.com